TW202339794A - 使用p—tau181水平之治療方法 - Google Patents
使用p—tau181水平之治療方法 Download PDFInfo
- Publication number
- TW202339794A TW202339794A TW111142860A TW111142860A TW202339794A TW 202339794 A TW202339794 A TW 202339794A TW 111142860 A TW111142860 A TW 111142860A TW 111142860 A TW111142860 A TW 111142860A TW 202339794 A TW202339794 A TW 202339794A
- Authority
- TW
- Taiwan
- Prior art keywords
- subject
- months
- antibody
- dose
- administered
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4709—Amyloid plaque core protein
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
- G01N2800/2821—Alzheimer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Neurosurgery (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Neurology (AREA)
- Hematology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Urology & Nephrology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Psychiatry (AREA)
- Genetics & Genomics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Hospice & Palliative Care (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263306060P | 2022-02-02 | 2022-02-02 | |
| US63/306,060 | 2022-02-02 | ||
| US202263269394P | 2022-03-15 | 2022-03-15 | |
| US63/269,394 | 2022-03-15 | ||
| US202263364617P | 2022-05-12 | 2022-05-12 | |
| US63/364,617 | 2022-05-12 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TW202339794A true TW202339794A (zh) | 2023-10-16 |
Family
ID=84488881
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW111142860A TW202339794A (zh) | 2022-02-02 | 2022-11-09 | 使用p—tau181水平之治療方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20250377367A1 (https=) |
| EP (1) | EP4473009A1 (https=) |
| JP (1) | JP2025506389A (https=) |
| KR (1) | KR20240142535A (https=) |
| AU (1) | AU2022439338A1 (https=) |
| CA (1) | CA3243435A1 (https=) |
| CL (1) | CL2024002309A1 (https=) |
| IL (1) | IL314581A (https=) |
| MX (1) | MX2024009492A (https=) |
| TW (1) | TW202339794A (https=) |
| WO (1) | WO2023149970A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025260029A1 (en) * | 2024-06-14 | 2025-12-18 | Eisai R&D Management Co., Ltd. | Method for quantifying amyloid beta protofibril |
| CN118777453B (zh) * | 2024-06-25 | 2025-04-08 | 上海交通大学医学院附属瑞金医院 | 一种基于液相色谱-串联质谱定量分析血液中仑卡奈单抗浓度的方法 |
| WO2026015877A1 (en) | 2024-07-12 | 2026-01-15 | Eisai R&D Management Co., Ltd. | Fluid biomarker |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2414772C (en) | 2000-07-07 | 2011-06-28 | Jan Naslund | Prevention and treatment of alzheimer's disease |
| SE0401601D0 (sv) | 2004-06-21 | 2004-06-21 | Bioarctic Neuroscience Ab | Protofibril specific antibodies and uses thereof |
| RU2429244C2 (ru) | 2006-03-23 | 2011-09-20 | Байоарктик Ньюросайенс Аб | Улучшенные селективные в отношении протофибрилл антитела и их применение |
| LT2448968T (lt) | 2009-06-29 | 2021-05-10 | Bioarctic Ab | Antikūnai, atpažįstantys n gale sutrumpintas amiloido protofibriles/oligomerus |
| JP5894939B2 (ja) | 2010-02-26 | 2016-03-30 | バイオアークティック ニューロサイエンス アーベー | プロトフィブリル結合抗体ならびにパーキンソン病、レビー小体型認知症および他のα−シヌクレイノパチーの治療および診断方法におけるこれらの使用 |
| WO2016005466A2 (en) | 2014-07-10 | 2016-01-14 | Bioarctic Neuroscience Ab | IMPROVED Aß PROTOFIBRIL BINDING ANTIBODIES |
| AU2018352308B2 (en) | 2017-10-16 | 2025-06-05 | Eisai R&D Management Co., Ltd. | Anti-tau antibodies and uses thereof |
| US20210324056A1 (en) * | 2018-07-24 | 2021-10-21 | Eisai R&D Management Co., Ltd. | Methods of treatment and prevention of alzheimer's disease |
| KR20220084095A (ko) * | 2019-10-22 | 2022-06-21 | 바이오젠 엠에이 인코포레이티드 | 알츠하이머병의 치료를 위한 항-베타-아밀로이드 항체 |
| RS67249B1 (sr) | 2020-03-20 | 2025-10-31 | Eisai R&D Man Co Ltd | Formulacije antitela visoke koncentracije protiv protofibrila amiloid beta peptida i metode njihove upotrebe |
-
2022
- 2022-11-09 AU AU2022439338A patent/AU2022439338A1/en active Pending
- 2022-11-09 CA CA3243435A patent/CA3243435A1/en active Pending
- 2022-11-09 IL IL314581A patent/IL314581A/en unknown
- 2022-11-09 WO PCT/US2022/079571 patent/WO2023149970A1/en not_active Ceased
- 2022-11-09 US US18/835,235 patent/US20250377367A1/en active Pending
- 2022-11-09 MX MX2024009492A patent/MX2024009492A/es unknown
- 2022-11-09 EP EP22822805.2A patent/EP4473009A1/en active Pending
- 2022-11-09 KR KR1020247029332A patent/KR20240142535A/ko active Pending
- 2022-11-09 TW TW111142860A patent/TW202339794A/zh unknown
- 2022-11-09 JP JP2024545951A patent/JP2025506389A/ja active Pending
-
2024
- 2024-07-31 CL CL2024002309A patent/CL2024002309A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CL2024002309A1 (es) | 2025-01-24 |
| KR20240142535A (ko) | 2024-09-30 |
| CA3243435A1 (en) | 2023-08-10 |
| JP2025506389A (ja) | 2025-03-11 |
| US20250377367A1 (en) | 2025-12-11 |
| AU2022439338A1 (en) | 2024-08-15 |
| MX2024009492A (es) | 2024-08-09 |
| WO2023149970A1 (en) | 2023-08-10 |
| IL314581A (en) | 2024-09-01 |
| EP4473009A1 (en) | 2024-12-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7676556B2 (ja) | 抗N3pGluアミロイドベータ抗体及びその使用 | |
| US20250163135A1 (en) | Biomarkers for alzheimer's disease treatment | |
| TW202339794A (zh) | 使用p—tau181水平之治療方法 | |
| TW202019471A (zh) | 阿茲海默症之治療及預防方法 | |
| JP7792428B2 (ja) | 抗アミロイドベータ抗体及びその使用 | |
| KR20250114372A (ko) | 타우(tau) pet 수준을 이용하는 치료 방법 | |
| TWI894689B (zh) | 抗N3pGlu類澱粉蛋白β抗體、其劑量及其用途 | |
| TW202328178A (zh) | 抗Aβ初原纖維抗體的皮下配製物及其使用方法 | |
| CN117940773A (zh) | 用于阿尔茨海默病治疗的生物标记物 | |
| CN118786141A (zh) | 使用p-tau181水平的治疗方法 | |
| EA052116B1 (ru) | Антитела к бета-амилоидному пептиду n3pglu и варианты их применения | |
| KR20260038283A (ko) | 항미생물 펩티드 | |
| WO2026075947A1 (en) | Dosing regimens for early alzheimer's disease | |
| KR20260022396A (ko) | 항-Aβ 프로토피브릴 항체를 사용한 치료 방법 | |
| WO2022251048A1 (en) | Anti-amyloid beta antibodies and uses thereof |